Skip to content

Author

Katsuya Yuki

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Autologous Glypican-3-Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102.

Findings support a manageable safety profile for TAK-102 and provide early evidence of biological activity in solid tumors, and are warranted to optimize dosing, improve CAR T-cell persistence, and evaluate efficacy in larger patient cohorts.

Y. Kuboki, T. Koyama, M. Ikeda et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.